| 000 | 01551 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250516095431.0 | ||
| 264 | 0 | _c20121204 | |
| 008 | 201212s 0 0 eng d | ||
| 022 | _a1748-717X | ||
| 024 | 7 |
_a10.1186/1748-717X-7-88 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aFraunholz, Ingeborg | |
| 245 | 0 | 0 |
_aHigh survivin expression as a risk factor in patients with anal carcinoma treated with concurrent chemoradiotherapy. _h[electronic resource] |
| 260 |
_bRadiation oncology (London, England) _cJun 2012 |
||
| 300 |
_a88 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAntineoplastic Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aAnus Neoplasms _xmetabolism |
| 650 | 0 | 4 | _aChemoradiotherapy |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aFluorouracil _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunohistochemistry |
| 650 | 0 | 4 |
_aInhibitor of Apoptosis Proteins _xbiosynthesis |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMitomycin _xadministration & dosage |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aRisk Factors |
| 650 | 0 | 4 | _aSurvivin |
| 700 | 1 | _aRödel, Claus | |
| 700 | 1 | _aDistel, Luitpold | |
| 700 | 1 | _aRave-Fränk, Marget | |
| 700 | 1 | _aKohler, Daniela | |
| 700 | 1 | _aFalk, Stefan | |
| 700 | 1 | _aRödel, Franz | |
| 773 | 0 |
_tRadiation oncology (London, England) _gvol. 7 _gp. 88 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1186/1748-717X-7-88 _zAvailable from publisher's website |
| 999 |
_c21864003 _d21864003 |
||